Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
21 Fevereiro 2024 - 6:05PM
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing
and precision medicine, will hold its fourth quarter earnings
conference call on Tuesday, February 27, 2024 at 4:30p.m. EST. The
company’s quarterly earnings will be released the same day after
the market closes.
During the call, Myriad management will provide a financial
overview and business update of the company’s performance for the
fourth quarter and full year 2023. Revenue and earnings guidance
for 2024 will also be shared.
A live webcast of the earnings conference call can be accessed
on Myriad’s Investor Relations website at investor.myriad.com. To
participate in the live conference call via telephone, please
register here. Upon registering, a dial-in number and unique PIN
will be provided to join the conference call. Following the
conference call, an archived webcast of the call will be available
at investor.myriad.com.
March Investor ConferencesManagement will also
be participating in the following investor conferences:
- The 45th Annual Raymond James & Associates Institutional
Investors Conference with a presentation from Paul J. Diaz,
president and CEO, and Scott Leffler, chief financial officer, on
March 4, 2024, at 4:35pm EST.
- The 44th Annual Cowen Health Care Conference with a fireside
chat featuring Sam Raha, chief operating officer, and Ben Wheeler,
chief financial officer – operations, on March 5, 2024, at 12:50pm
EST.
A live and archived webcast of both presentations can be viewed
in the investor relations section of Myriad’s website at
investor.myriad.com.
About Myriad Genetics Myriad Genetics is a
leading genetic testing and precision medicine company dedicated to
advancing health and well-being for all. Myriad develops and offers
genetic tests that help assess the risk of developing disease or
disease progression and guide treatment decisions across medical
specialties where genetic insights can significantly improve
patient care and lower healthcare costs. For more information,
visit www.myriad.com.
Investor ContactMatt Scalo(801)
584-3532IR@myriad.com
Media ContactGlenn Farrell(385)
318-3718PR@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Myriad Genetics (NASDAQ:MYGN)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024